Comparing cutaneous research funded by the US National Institutes of Health (NIH) with the US skin disease burden - 17/08/15
Abstract |
Background |
Disease burden should be an important component for guiding research funding.
Objective |
We sought to examine the relationship between dermatologic research funded from 2012 to 2013 by the National Institutes of Health (NIH) and US skin disease burden as measured by disability-adjusted life years in the Global Burden of Disease 2010 study.
Methods |
A cross-sectional analysis was independently performed by 2 researchers who matched projects from the 2012 to 2013 NIH Research Portfolio Online Reporting Tools with 15 skin conditions and their respective disability-adjusted life years from Global Burden of Disease 2010.
Results |
The NIH funded 1108 projects spanning the 15 skin conditions. Melanoma received almost half of the total skin condition budget (49.5%). Melanoma, nonmelanoma skin cancer, and leprosy were funded above what would be suggested by their disease burden, whereas dermatitis, acne vulgaris, pruritus, urticaria, decubitus ulcer, fungal skin diseases, alopecia areata, cellulitis, and scabies appeared underfunded. Bacterial skin diseases, viral skin diseases, and psoriasis were well matched with disease burden.
Limitations |
Disease burden is one of many factors that may be used to guide priority-setting decisions.
Conclusion |
Skin disease burden measured by disability-adjusted life year metrics partially correlates with NIH funding prioritization. Comparing US disease burden with NIH funding suggests possible underfunded and overfunded skin diseases.
Le texte complet de cet article est disponible en PDF.Key words : dermatitis, disability-adjusted life years, disease burden, leprosy, melanoma, National Institutes of Health, priority setting, skin conditions
Abbreviations used : DALY, GBD, IC, IOM, NIH, NMSC
Plan
| Ms Hagstrom, Ms Patel, and Ms Karimkhani are co-first authors. |
|
| The Global Burden of Disease Study 2010 was supported in part by the Bill and Melinda Gates Foundation. Drs Dellavalle, Weinstock, Dunnick, and Armstrong receive a salary from the US Department of Veterans Affairs. Dr Dellavalle is also supported by grants from the Centers for Disease Control and Prevention (Grant 3U48DP001938-04S1) and National Institutes of Health (NIH) (Grant NCI R21 CA173654). Drs Dellavalle, Weinstock, and Margolis previously received NIH funding for research grants. All other authors have no relevant funding/support. |
|
| Disclosure: Dr Dellavalle is chair of the Colorado Skin Cancer Task Force and has served as a co-investigator on National Institutes of Health (NIH)-funded projects. The Department of Veterans Affairs, Centers for Disease Control and Prevention, and NIH had no role in the design and execution of the study and any opinions expressed herein do not necessarily reflect the opinions of these organizations. Ms Boyers, Ms Hagstrom, Ms Patel, Ms Karimkhani, and Drs Williams, Hay, Weinstock, Armstrong, Dunnick, and Margolis have no conflicts of interest to declare. |
Vol 73 - N° 3
P. 383 - septembre 2015 Retour au numéro
Article précédent
- CME examination
- Commentary: Setting priorities for research funding at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Stephen I. Katz
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?